Alessandra Cinque
Overview
Explore the profile of Alessandra Cinque including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
111
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Trevisani F, Floris M, Trepiccione F, Rosiello G, Capasso G, Pani A, et al.
J Clin Med
. 2024 Nov;
13(21).
PMID: 39518690
: Acute Kidney Injury (AKI) and Chronic Kidney Disease (CKD) are significant risks for kidney cancer (KC) patients undergoing partial (PN) or radical nephrectomy (RN) and for living kidney donors...
2.
Nardone I, Wolde Sellasie S, Cinque A, Tacchi G, Zaccaria S, Giusto C, et al.
Endocr Metab Immune Disord Drug Targets
. 2024 Aug;
PMID: 39108109
Background: Patients with permanent hypoparathyroidism experience an impaired quality of life, due to acute and chronic complications that may affect several organs, with an increased risk of hospitalisation and death....
3.
Trevisani F, Simeoni M, Bettiga A, Cinque A, Floris M
Kidney Blood Press Res
. 2024 Apr;
49(1):336-344.
PMID: 38636485
Background: In the era of precision medicine, determining reliable renal function assessment remains a critical and debatable issue, especially in nephrology and oncology. Summary: This paper delves into the significance...
4.
Trevisani F, Di Marco F, Quattrini G, Lepori N, Floris M, Valsecchi D, et al.
Front Oncol
. 2023 Jun;
13:1173578.
PMID: 37361572
Background: In locally advanced head and neck squamous cell carcinoma (LA-SCCHN) at least 200mg/m (standard dose 300 mg/m) of cisplatin concomitant with radiotherapy represents the standard of care, both in...
5.
Trevisani F, Floris M, Cinque A, Bettiga A, DellAntonio G
Nephron
. 2022 Dec;
147(5):266-271.
PMID: 36529122
A reliable assessment of renal function is of paramount importance in several clinical assets in order to tailor a personalized medical approach. CKD classification system, created in 2002 by the...
6.
Cinque A, Minnei R, Floris M, Trevisani F
Cancers (Basel)
. 2022 Nov;
14(21).
PMID: 36358771
Von Hippel-Lindau (VHL) disease is an autosomal dominant inherited cancer syndrome caused by germline mutations in the VHL tumor suppressor gene, characterized by the susceptibility to a wide array of...
7.
Trevisani F, Floris M, Vago R, Minnei R, Cinque A
Cells
. 2022 May;
11(10).
PMID: 35626699
Papillary renal cell carcinoma (pRCC) represents the second most common subtype of renal cell carcinoma, following clear cell carcinoma and accounting for 10-15% of cases. For around 20 years, pRCCs...
8.
Cianflone F, Lazarevic D, Palmisano A, Fallara G, Larcher A, Freschi M, et al.
Transl Androl Urol
. 2022 Mar;
11(2):149-158.
PMID: 35280651
Background: The combination of radiomic and transcriptomic approaches for patients diagnosed with small clear-cell renal cell carcinoma (ccRCC) might improve decision making. In this pilot and methodological study, we investigate...
9.
Trevisani F, Floris M, Minnei R, Cinque A
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269747
Renal oncocytoma represents the most common type of benign neoplasm that is an increasing concern for urologists, oncologists, and nephrologists due to its difficult differential diagnosis and frequent overtreatment. It...
10.
Cinque A, Capasso A, Vago R, Floris M, Lee M, Minnei R, et al.
Int J Mol Sci
. 2022 Mar;
23(5).
PMID: 35269744
Upper urinary tract urothelial carcinoma (UTUC) represents a minor subgroup of malignancies arising in the urothelium of the renal pelvis or ureter. The estimated annual incidence is around 2 cases...